All In Biotech

Free tool

Drugs in development

Investigational drugs and biologics in industry-sponsored Phase 2 and Phase 3 trials that are active or finished in the last two years, and that FDA has not approved. Built from 10,322 ClinicalTrials.gov records, with code names and generic names merged. For approved drugs, use Drug Search.

Last checked: Nov 20, 2026Latest source record: rebuilt Nov 18, 2026Source: ClinicalTrials.govMethods & limitations

Drugs in development

3,685

Not FDA-approved

In Phase 3

1,424

Highest phase reached

Matching your filters

52

Reset

52 drugs in development

Names, sponsors and conditions come from the trial records. Click a drug for its trials.

  • AZD0120GC012FPhase 39 trials

    AstraZeneca · Newly Diagnosed Multiple Myeloma (NDMM), Relapsed AL Amyloidosis, Refractory AL Amyloidosis

  • EtentamigABBV-383, TNB-383BPhase 38 trials

    AbbVie · Multiple Myeloma, Relapsed or Refractory Multiple Myeloma, Amyloid Light Chain (AL) Amyloidosis

  • BMS-986348CC-92480, mezigdomidePhase 37 trials

    Bristol Myers Squibb · Multiple Myeloma, Relapsed or Refractory Multiple Myeloma

  • CM336group, QiShen YiQi Dripping Pills 3 bagsPhase 37 trials

    Keymed Biosciences Co.Ltd · Multiple Myeloma (MM), Primary Light-Chain Amyloidosis, Primary Immune Thrombocytopenia

  • GR1803Velinotamig specified specified days., CLN-803Phase 37 trials

    Genrix (Shanghai) Biopharmaceutical Co., Ltd. · Multiple Myeloma, Immune Thrombocytopenia (ITP), Warm Autoimmune Hemolytic Anemia (WAIHA)

  • JNJ-79635322Ramantamig, BCMAxGPRC5DxCD3Phase 37 trials

    Johnson & Johnson (Janssen) · Multiple Myeloma

  • Cilta-celJNJ-68284528Phase 36 trials

    Johnson & Johnson (Janssen) · Multiple Myeloma

  • CM313Phase 36 trials

    Keymed Biosciences Co.Ltd · Systemic Lupus Erythematosus, Primary Immune Thrombocytopenia, Platelet Transfusion Refractoriness

  • Anitocabtagene AutoleucelCART-ddBCMAPhase 34 trials

    Gilead Sciences · Multiple Myeloma, Newly Diagnosed Multiple Myeloma

  • CevostamabRO7187797Phase 34 trials

    Roche (Genentech) · Multiple Myeloma

  • IBI3003Phase 34 trials

    Innovent Biologics (Suzhou) Co. Ltd. · Multiple Myeloma, Relapsed or Refractory Multiple Myeloma

  • SCTC21CPhase 34 trials

    Sinocelltech Ltd. · IgA Nephropathy, Multiple Myeloma (MM), Systemic Lupus Erythematosus (SLE)

  • SG301Phase 33 trials

    Hangzhou Sumgen Biotech Co., Ltd. · Systemic Lupus Erythematosus (SLE), Relapsed/Refractory Multiple Myeloma, Antibody Mediated Rejection

  • Arlocabtagene AutoleucelBMS-986393, GPRC5D CAR T cellsPhase 32 trials

    Bristol Myers Squibb · Multiple Myeloma, Relapsed or Refractory Multiple Myeloma (RRMM)

  • bb2121BMS-986395Phase 32 trials

    Bristol Myers Squibb · Multiple Myeloma

  • BCD-248Phase 32 trials

    Biocad · Relapsed/Refractory Multiple Myeloma, Myeloma Multiple

  • BL-8040Phase 32 trials

    BioLineRx, Ltd. · Multiple Myeloma, Pancreatic Adenocarcinoma

  • CLR 131I-131-CLR1404, Iopofosine I 131 single dosePhase 32 trials

    Cellectar Biosciences, Inc. · Waldenstrom Macroglobulinemia, Multiple Myeloma, Chronic Lymphocytic Leukemia

  • Equecabtagene AutoleucelFUCASOPhase 32 trials

    Nanjing IASO Biotechnology Co., Ltd. · Refractory Immune-mediated Necrotizing Myopathy, Multiple Myeloma

  • Purinostat MesylatePhase 32 trials

    Chengdu Zenitar Biomedical Technology Co., Ltd · Relapsed or Refractory Multiple Myeloma (RRMM), Recurrent and Refractory Diffuse Large B-cell Lymphoma

  • QLS32015Phase 32 trials

    Qilu Pharmaceutical Co., Ltd. · Relapsed or Refractory Multiple Myeloma

  • QLS4131Phase 32 trials

    Qilu Pharmaceutical Co., Ltd. · Malignant Plasma Cell Neoplasms, Relapsed or Refractory Multiple Myeloma

  • TQB2934Phase 32 trials

    Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Multiple Myeloma, Systemic Light Chain Amyloidosis

  • HLX15Phase 31 trial

    Shanghai Henlius Biotech · Newly Diagnosed Multiple Myeloma

  • Relma-celCAR, CD19-targeted Chimeric Antigen Receptor T CellsPhase 23 trials

    Shanghai Ming Ju Biotechnology Co., Ltd. · Non-Hodgkin Lymphoma, Large B-cell Lymphoma, Multiple Myeloma

  • BMS-986158Phase 22 trials

    Bristol Myers Squibb · Myelofibrosis, Multiple Myeloma

  • FeladilimabGSK3359609Phase 22 trials

    GSK · Multiple Myeloma

  • IDP-121Phase 22 trials

    IDP Discovery Pharma S.L. · Small Cell Lung Cancer ( SCLC ), Multiple Myeloma (MM), Diffuse Large B-Cell Lymphoma, Not Otherwise Specified

  • MBS314Phase 22 trials

    Beijing Mabworks Biotech Co., Ltd. · Relapsed or Refractory Multiple Myeloma, Multiple Myeloma

  • REGN5459Vonsetamig, BCMAxCD3Phase 22 trials

    Regeneron · Chronic Kidney Disease (CKD), Relapsed Multiple Myeloma, Refractory Multiple Myeloma

  • ABBV-2001Phase 21 trial

    AbbVie · Multiple Myeloma

  • AZD0305Phase 21 trial

    AstraZeneca · Multiple Myeloma

  • AZD4045Phase 21 trial

    AstraZeneca · Relapsed or Refractory Multiple Myeloma

  • BT02Phase 21 trial

    Biotroy Therapeutics · Relapsed or Refractory Hematologic Malignancies, Leukemia, Lymphoma

  • CD38Phase 21 trial

    Shandong New Time Pharmaceutical Co., LTD · Relapsed or Refractory Multiple Myeloma

  • CT071Phase 21 trial

    CARsgen Therapeutics Co., Ltd. · Multiple Myeloma, Primary Plasma Cell Leukemia

  • CYT-0851Phase 21 trial

    Cyteir Therapeutics, Inc. · Malignancy, Non-hodgkin Lymphoma, Multiple Myeloma

  • Eque-celFully Human BCMA Chimeric Antigen Receptor Autologous T CellPhase 21 trial

    Nanjing IASO Biotechnology Co., Ltd. · Relapsed/Refractory Multiple Myeloma

  • F182112Phase 21 trial

    Shandong New Time Pharmaceutical Co., LTD · Relapsed or Refractory Multiple Myeloma

  • GPC-100Phase 21 trial

    GPCR Therapeutics, Inc. · Multiple Myeloma

  • GSK3174998Phase 21 trial

    GSK · Multiple Myeloma

  • HDP-101Phase 21 trial

    Heidelberg Pharma AG · Multiple Myeloma, Plasma Cell Disorder

  • HuL001Phase 21 trial

    HuniLife Biotechnology, Inc. · Multiple Myeloma Refractory

  • IDP-023Phase 21 trial

    Indapta Therapeutics, INC. · NHL, Multiple Myeloma, Blood Cancer

  • LBL-034Phase 21 trial

    Nanjing Leads Biolabs Co.,Ltd · Relapsed/Refractory Multiple Myeloma

  • OriCAR-017Phase 21 trial

    OriCell Therapeutics Co., Ltd. · Relapsed and/or Refractory Multiple Myeloma

  • REGN17372Phase 21 trial

    Regeneron · Relapsed Refractory Multiple Myeloma (RRMM)

  • REGN7945Phase 21 trial

    Regeneron · Relapsed/Refractory Multiple Myeloma

  • SG2918Phase 21 trial

    Hangzhou Sumgen Biotech Co., Ltd. · Relapsed/Refractory Multiple Myeloma

  • STI-6129Phase 21 trial

    Zhejiang ACEA Pharmaceutical Co. Ltd. · Relapsed or Refractory Multiple Myeloma

Page 1 of 2Older

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.